Most Read Articles
Tristan Manalac, 06 Nov 2018
Intravenous cefiderocol thrice daily is noninferior to imipenem-cilastatin for treating complicated urinary tract infection (UTI) patients with multidrug-resistant, Gram-negative infections, according to a recent study.
01 Nov 2018
Genotype 4 hepatitis E virus infection does not appear to be correlated with acute, nontraumatic neurologic disorders, according to a recent China study.
01 Nov 2018
In patients with genotype 3 hepatitis C virus (HCV) infection and decompensated cirrhosis, the rate of achieving sustained virologic response 12 weeks after treatment (SVR12) is high with treatment regimens consisting of sofosbuvir and velpatasvir with or without ribavirin, according to the results of a phase II trial. However, the rate appears to be lower in the subgroup of patients with baseline resistance-associated substitutions in nonstructural protein 5A.
07 Nov 2018
In infants with early-life acute respiratory infection (ARI) with respiratory syncytial virus (RSV), elevated nasopharyngeal Lactobacillus levels protect against wheezing illnesses at 2 years of age, a recent study has found.

Product Highlight - Zepatier

01 May 2018
ZEPATIER - Elbasvir 50 mg, grazoprevir 100 mg FC tab - Merck Sharp & Dohme
• A fixed-dose combination of a second-generation NS3/4A protease inhibitor and NS5A inhibitor1,2
• ZEPATIER is indicated for the treatment of Chronic Hepatitis C Genotypes 1 and 4 Infection in adults1.
• Powerful CURE* Across Multiple Patient Types1

*Cure of hepatitis C virus (HCV) infection=sustained virologic response, the primary end point in all studies, defined as HCV ribonucleic acid (RNA) less than the lower limit of quantification (LLOQ) at 12 weeks after the cessation of treatment (SVR12).1,3

References:
1. Zepatier Package Insert, 10 August 2017.
2. Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int. 2013;33(suppl 1):80–84.
3. European Association for the Study of the Liver. Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199–236.

Further information is available in section 8p, New In This Issue and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 06 Nov 2018
Intravenous cefiderocol thrice daily is noninferior to imipenem-cilastatin for treating complicated urinary tract infection (UTI) patients with multidrug-resistant, Gram-negative infections, according to a recent study.
01 Nov 2018
Genotype 4 hepatitis E virus infection does not appear to be correlated with acute, nontraumatic neurologic disorders, according to a recent China study.
01 Nov 2018
In patients with genotype 3 hepatitis C virus (HCV) infection and decompensated cirrhosis, the rate of achieving sustained virologic response 12 weeks after treatment (SVR12) is high with treatment regimens consisting of sofosbuvir and velpatasvir with or without ribavirin, according to the results of a phase II trial. However, the rate appears to be lower in the subgroup of patients with baseline resistance-associated substitutions in nonstructural protein 5A.
07 Nov 2018
In infants with early-life acute respiratory infection (ARI) with respiratory syncytial virus (RSV), elevated nasopharyngeal Lactobacillus levels protect against wheezing illnesses at 2 years of age, a recent study has found.